Medical Information

Nexletol is a novel oral cholesterol lowering drug, particularly suitable for patients with statin intolerance. As an ATP citrate lyase inhibitor, it reduces LDL-C levels through a unique mechanism, with a standard dose of 180mg taken with meals daily. Clinical data shows that monotherapy can reduce LDL-C by 28% and has a synergistic effect when combined with statins. Common adverse reactions include muscle pain and mild elevation of liver enzymes.

1. Core treatment advantages

(1) Target innovation: Selective inhibition of liver ATP citrate lyase, blocking the upstream pathway of cholesterol synthesis, complementary to the mechanism of action of statins.

(2) Good tolerability: Phase III clinical trials have shown that the discontinuation rate due to adverse reactions is only 5.4%, significantly lower than the common discontinuation rate of statins.

(3) Stable therapeutic effect: Continuous medication for 12 weeks can achieve the maximum lipid-lowering effect, and the decrease in LDL-C remains in the range of 18% -28%.

Application for patients with statin intolerance

(1) Alternative solution: For patients with statin related myopathy or liver enzyme abnormalities, it can be used as a first-line alternative treatment option.

(2) Joint strategy: When used in combination with ezetimibe, LDL-C can be reduced by up to 48%, approaching the effect of high-intensity statins.

(3) Special populations: Elderly individuals and those with renal insufficiency do not need to adjust their dosage, but need to monitor changes in uric acid levels.

3 Key points of medication management

(1) Medication specification: Must be taken with meals to improve bioavailability, whole tablet should not be chewed.

(2) Monitoring requirements: Liver function should be tested before treatment, ALT should be rechecked after 12 weeks, and long-term medication should be monitored every 6 months.

(3) Omission treatment: If a missed dose is found on the same day, it should be taken immediately and the normal medication time should be restored the next day.

4 Security Features

(1) Muscle safety: The incidence of muscle pain is 5.1%, much lower than statins, and the risk of rhabdomyolysis is extremely low.

(2) Metabolic effects: May increase blood uric acid levels by 1-2mg/dL, gout patients need to strengthen monitoring.

(3) Hepatotoxicity: The incidence of ALT>3 times ULN is 2.3%, mostly transient abnormalities.

5 Clinical positioning

(1) Applicable scenarios: As the primary treatment option for patients with statin intolerance, or as a combination therapy for those who have not met statin treatment standards.

(2) Treatment objective: Suitable for moderate risk patients who require a 15% -30% reduction in LDL-C.

(3) Restrictive factors: Patients with severe liver injury are prohibited from using it, and pregnant and lactating women need to evaluate the risk benefit ratio.